Your browser doesn't support javascript.
loading
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Hashemian, Seyed Mohammad Reza; Pourhanifeh, Mohammad Hossein; Hamblin, Michael R; Shahrzad, Mohammad Karim; Mirzaei, Hamed.
Afiliação
  • Hashemian SMR; Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Pourhanifeh MH; School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
  • Hamblin MR; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa.
  • Shahrzad MK; Department of Internal Medicine and Endocrinology, ShohadaeTajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: mk_shahrzad@yahoo.com.
  • Mirzaei H; Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, IR, Iran. Electronic address: h.mirzaei2002@gmail.com.
Biomed Pharmacother ; 146: 112517, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34902743
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / RNA Polimerase Dependente de RNA / Citidina / COVID-19 / Tratamento Farmacológico da COVID-19 / Hidroxilaminas Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / RNA Polimerase Dependente de RNA / Citidina / COVID-19 / Tratamento Farmacológico da COVID-19 / Hidroxilaminas Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article